Scalper1 News
Biotech OncoMed (OMED) announced Tuesday that it’s collaborating with Celgene (CELG) to jointly develop and market its anti-cancer stem cell products, sending OncoMed stock up 75% in the stock market today. Celgene agreed to pay OncoMed $155 million up front, with further payments contingent on the products meeting certain clinical, regulatory and commercial milestones. OncoMed said payments for its most developed candidate, demcizumab, could Scalper1 News
Scalper1 News